Cue biopharma reports second quarter 2022 financial results

Boston, aug. 04, 2022 (globe newswire) -- cue biopharma, inc. (nasdaq: cue), a clinical-stage biopharmaceutical company developing a novel class of injectable biologics to selectively engage and modulate tumor-specific t cells directly within the patient's body, reported today second quarter 2022 financial results. the company will host a business update call and webcast on tuesday, august 23, 2022 at 4:30 p.m. edt. live and archived versions of the event can be accessed via the company's website.
CUE Ratings Summary
CUE Quant Ranking